NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics is attractive because its core clinical business is showing sustained improvement, with four consecutive quarterly top-line beats, five consecutive quarters of double-digit growth, and Q3’26 revenue of about $209 million, up 11% year over year and ahead of expectations. The outlook is further supported by accelerating higher-margin NGS demand, with Q2’26 NGS revenue up 26% and Q3’26 growth at 28%, plus improving pricing as ASPs rose 12% to $515 per test and adjusted EBITDA reached $14 million. Its MRD and liquid biopsy opportunity is also de-risking through Medicare coverage wins for RaDaR ST and PanTracer LBx, while the stock still trades at roughly 3x 2027 Street revenue versus about 11x for peers, suggesting meaningful valuation catch-up potential.

NeoGenomics is operating near breakeven on an adjusted EPS and EBITDA basis, leaving little margin for error and no assurance of sustainable profitability. Its outlook is weakened by intense competition in precision oncology diagnostics, the risk of falling behind rivals on test innovation and aggressive commercialization, and exposure to volatile reimbursement, regulatory changes, and budget-driven ordering swings from pharma and the VA. Management also faces execution risk from Tempus partnerships and the possibility that greater reinvestment or weaker market share could keep revenue growth at 7% or less while margins remain pressured.